These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 18550452

  • 1. Bacterial contamination in the environment of hospitalised children with cystic fibrosis.
    Ferroni A, Werkhauser-Bertrand A, Le Bourgeois M, Beauvais R, Vrielynck S, Durand C, Lenoir G, Berche P, Sermet-Gaudelus I.
    J Cyst Fibros; 2008 Nov; 7(6):477-82. PubMed ID: 18550452
    [Abstract] [Full Text] [Related]

  • 2. Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces.
    Panagea S, Winstanley C, Walshaw MJ, Ledson MJ, Hart CA.
    J Hosp Infect; 2005 Feb; 59(2):102-7. PubMed ID: 15620443
    [Abstract] [Full Text] [Related]

  • 3. Bacterial contamination of cystic fibrosis clinics.
    Zuckerman JB, Zuaro DE, Prato BS, Ruoff KL, Sawicki RW, Quinton HB, Saiman L, Infection Control Study Group.
    J Cyst Fibros; 2009 May; 8(3):186-92. PubMed ID: 19250885
    [Abstract] [Full Text] [Related]

  • 4. Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center.
    Campana S, Taccetti G, Ravenni N, Masi I, Audino S, Sisi B, Repetto T, Döring G, de Martino M.
    J Cyst Fibros; 2004 Aug; 3(3):159-63. PubMed ID: 15463902
    [Abstract] [Full Text] [Related]

  • 5. A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting.
    O'Malley CA, VandenBranden SL, Zheng XT, Polito AM, McColley SA.
    Respir Care; 2007 Mar; 52(3):258-62. PubMed ID: 17328823
    [Abstract] [Full Text] [Related]

  • 6. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
    Bradbury R, Champion A, Reid DW.
    Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
    [Abstract] [Full Text] [Related]

  • 7. Prevalence of toxin producing strains of Staphylococcus aureus in a pediatric burns unit.
    Khojasteh VJ, Edwards-Jones V, Childs C, Foster HA.
    Burns; 2007 May; 33(3):334-40. PubMed ID: 17234351
    [Abstract] [Full Text] [Related]

  • 8. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR, Pressler T, Høiby N.
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [Abstract] [Full Text] [Related]

  • 9. Microbial contamination of nebulizers in the home treatment of cystic fibrosis.
    Blau H, Mussaffi H, Mei Zahav M, Prais D, Livne M, Czitron BM, Cohen HA.
    Child Care Health Dev; 2007 Jul; 33(4):491-5. PubMed ID: 17584406
    [Abstract] [Full Text] [Related]

  • 10. Low level of bacterial contamination of mist tents used in home treatment of cystic fibrosis patients.
    Jakobsson B, Hjelte L, Nyström B.
    J Hosp Infect; 2000 Jan; 44(1):37-41. PubMed ID: 10633052
    [Abstract] [Full Text] [Related]

  • 11. High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation.
    Molina A, Del Campo R, Máiz L, Morosini MI, Lamas A, Baquero F, Cantón R.
    J Antimicrob Chemother; 2008 Nov; 62(5):961-7. PubMed ID: 18647744
    [Abstract] [Full Text] [Related]

  • 12. Pseudomonas aeruginosa diversity in distinct paediatric patient groups.
    Tramper-Stranders GA, van der Ent CK, Wolfs TF, Kimpen JL, Fleer A, Johansen U, Johansen HK, Høiby N.
    Clin Microbiol Infect; 2008 Oct; 14(10):935-41. PubMed ID: 18752596
    [Abstract] [Full Text] [Related]

  • 13. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis.
    Vassal S, Taamma R, Marty N, Sardet A, d'athis P, Brémont F, Dalphin ML, Plésiat P, Rault G, Thubert J, Dominique S, Lemeland JF, Derelle J, Blech MF, Roussey M, Perrin M, Sautegeau A.
    Am J Infect Control; 2000 Oct; 28(5):347-51. PubMed ID: 11029133
    [Abstract] [Full Text] [Related]

  • 14. Transmission of a multiresistant Pseudomonas aeruginosa strain at a German University Hospital.
    Pitten FA, Panzig B, Schröder G, Tietze K, Kramer A.
    J Hosp Infect; 2001 Feb; 47(2):125-30. PubMed ID: 11170776
    [Abstract] [Full Text] [Related]

  • 15. [Evaluation of a new E-test method for antimicrobial sensitivity testing of Pseudomonas aeruginosa isolates from cystic fibrosis].
    Zebouh M, Thomas C, Honderlick P, Lemee L, Segonds C, Wallet F, Husson MO.
    Pathol Biol (Paris); 2005 Feb; 53(8-9):490-4. PubMed ID: 16087300
    [Abstract] [Full Text] [Related]

  • 16. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis.
    Ferroni A, Guillemot D, Moumile K, Bernede C, Le Bourgeois M, Waernessyckle S, Descamps P, Sermet-Gaudelus I, Lenoir G, Berche P, Taddei F.
    Pediatr Pulmonol; 2009 Aug; 44(8):820-5. PubMed ID: 19598278
    [Abstract] [Full Text] [Related]

  • 17. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
    Etherington C, Hall M, Conway S, Peckham D, Denton M.
    J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
    [Abstract] [Full Text] [Related]

  • 18. Biomarkers of neutrophilic inflammation in exhaled air of cystic fibrosis children with bacterial airway infections.
    Bodini A, D'Orazio C, Peroni D, Corradi M, Folesani G, Baraldi E, Assael BM, Boner A, Piacentini GL.
    Pediatr Pulmonol; 2005 Dec; 40(6):494-9. PubMed ID: 16229003
    [Abstract] [Full Text] [Related]

  • 19. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
    Hansen CR, Pressler T, Hoiby N, Johansen HK.
    J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
    [Abstract] [Full Text] [Related]

  • 20. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK.
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.